CASE STUDY

From paper to practise – a case study in PUPSIT

27 April 2022
Fill Finish

The context

Committing to a pre-use post-sterilization integrity testing (PUPSIT) strategy is a significant undertaking because, while some regulatory bodies recommend it, it may compromise downstream sterility and its implementation is associated with increased process complexity. This is why PUPSIT continues to generate considerable debate in the biopharmaceutical industry. To help support informed decision-making in this area, the BioPhorum/PDA Sterilizing Filtration Quality Risk Management Consortium has produced a series of articles. One of these is a paper titled Strategy roadmap for the implementation of a risk-based approach to pre-use post-sterilization integrity testing (PUPSIT). This allows companies to use scientific data and risk-based approaches to make and defend decisions related to PUPSIT.

Roche is one of the companies that has used the document to develop an internal position paper on PUPSIT and create its own risk-based approach, which is based on the BioPhorum/PDA PUPSIT strategy.

The story

“We’re a large company with different manufacturing sites and multiple filling lines in each site,” said Marc Steffens, Global Project Manager at Roche. “So it’s always been a challenge to establish harmonized processes, approaches, and strategies across our network. The same has been true for PUPSIT. The internal PUPSIT landscape is very diverse, and we have some sites and filling lines that do PUPSIT, while others don’t. As a result, we didn’t have a fully consistent strategy for how to assess the need for PUPSIT based on scientific considerations.”

Steffens added that the standardization of processes and the harmonization across the networks have always been key topics for Roche, so the BioPhorum/PDA consortium work is highly valued. “Based on this work, we have been able to establish guidelines to ensure that each site and each filling line is assessing this topic in the same manner. This will also improve our position when discussing our strategy with regulators or inspectors. For example, where we received previous observations, while not explicitly related to PUPSIT, inspectors noticed that one site does it one way while another does it differently. This leads to another critical step for us, towards a consistent approach.”

Steffens said that BioPhorum’s paper added value because Roche was looking for a more consistent strategy for PUPSIT as each site had previously created individual assessments. 

These were not necessarily done in the same way and with the same focus. Most of the assessments focused on the risk of using a flawed, non-integral filter, but disregarded the product properties that could lead to clogging of a flawed membrane. But it’s the combination of these two issues that results in a flaw-masking risk, i.e., the only scientific trigger for PUPSIT.
Marc Steffens, Global Project Manager at Roche

The outcomes

Steffens added that a significant change was that Roche was now applying an industry approach to PUPSIT. “This is important as it means we’re speaking as an industry, which helps us to, for example, defend our position in front of regulators.” He also commented that, previously, Roche had already used risk-based assessments but that the BioPhorum work had helped the team incorporate additional risk factors such as the flaw masking risk. Kewei Yang, Principal Scientist/Pharmaceutical Project Leader at Roche, explained this industry approach also helped the global roll-out of the new guidance. “We translated the BioPhorum work into our first internal guidance on this topic, for which we got endorsement and agreement from all our different manufacturing sites. It meant we now have an agreed global internal strategy for interpreting the EMA’s requirements on PUPSIT. Different sites used to interpret the regulatory requirements and prepared their risk assessment in their own way, so the outcomes from each site were different. Now we are aligning our strategy across sites and countries.” Roche has not only started to implement the BioPhorum approach but has already taken the next step. “After creating our internal guidance in 2021,” said Steffens, “we’re now in discussions with the different sites on setting up a risk assessment template to provide end-users with concrete and specific guidance on how to assess the flaw-masking risk. “One outcome of the end-user assessments could be that PUPSIT doesn’t make sense from a scientific perspective and hence may justify the removal of that step. But we’re just at the beginning of the process and the implementation will continue over the next few years. We haven’t had any inspection or audits in the last few months where PUPSIT was challenged, so we haven’t yet had any feedback on the strategy we’re now applying.”

Lessons learned

Steffens said that communication and dialogue, especially with health authorities, were important. “Once the BioPhorum/PDA consortium started these discussions, it soon became clear that we all have the same problems and questions, and that each company is struggling with PUPSIT. So, it’s also essential to be transparent on what we’re doing and what our strategy looks like. As PUPSIT is a compliance-related topic, discussions should include not only technical subject matter experts but also those from the quality department.” Yang explained he had learned a lot from the discussions in the BioPhorum team and that the publication would be valuable to the whole pharmaceutical industry. “It has been a great experience to join the BioPhorum discussions with experts from the other companies. These help us challenge our opinions and share our knowledge and know-how. A lesson learned is the importance of communicating with the different stakeholders; for example, our manufacturing colleagues from the different drug product sites, QA teams, and global functions. Communication is essential as this helped us get an endorsement from the different sides and ultimately establish a company guidance on this topic.”

NEWS
A view from industry on the implication of the new Annex 1 requirements on visual inspection process
NEWS
Maine and Minnesota – the BioPhorum responses to US state PFAS consultations
NEWS
BioPhorum Supply Partner has become Supply Resilience
NEWS
BioPhorum’s sustainability ambition – let’s move out of the holding pattern
NEWS
Building a resilient business means adopting water stewardship

Advanced Therapy Medicinal Products

Advanced Therapy Medicinal Products support the quest for better and faster development of cell, gene and RNA therapies​ through connecting therapy developers, contract manufacturing, and testing organizations to gain an understanding and respond to the challenges faced by the advanced therapeutics industry.

Development Group

Development Group accelerates and improves the development process of biopharmaceutical medicines for the benefit of the patient. Replacing isolation with collaboration by providing a “safe” space where subject matter experts can work on sharing solutions and best practice on emerging industry trends, implementation of new technologies and common issues whilst ensuring their intellectual property and confidentiality is protected.

Drug Substance

Drug Substance advances excellence in drug substance manufacturing and testing, acting as an industry voice to accelerate technology adoption, implement post-approval change more rapidly and increase confidence in maintaining compliance.

Fill Finish

Fill Finish accelerates development and acceptance of sustainable world-class filling and packaging operations for drug product which meets the future needs of patients. Through innovative solutions resulting from the sharing of expertise, we can overcome common performance challenges and deliver on quality and regulatory compliance.

Information Technology

Information Technology accelerates digital maturity across the ​global pharmaceutical manufacturing industry.

Quality

BioPhorum Quality provides a dedicated, safe space for quality professionals from biomanufacturers and contract organizations to coalesce and enhance effective collaboration to address shared industry challenges.

Regulatory-CMC

Regulatory CMC brings leaders together who have a common goal – to improve access to medicines through innovation in the Regulatory ecosystem. It provides a dedicated space for strategic leadership and a coordinated industry voice, to move from divergence to convergence.

Supply Chain to Patient

Supply Chain to Patient transforms the performance of global pharmaceutical clinical and commercial outbound supply chains through industry collaboration by creating transparent patient-centric, resilient and agile E2E supply chains, that consistently deliver high-quality medicines ensuring an uninterrupted supply to patients.

Supply Resilience

Supply Resilience is a trusted advisory group and collaboration that is the engine for driving change across the global industry for all things relevant to the inbound supply chain. Addressing the challenges of complexity, resilience, cost, sustainability, and innovation.

Sustainability

Sustainability enables the industry’s transition to a low carbon, circular future – supporting members to improve patient health while respecting the planet. We activate multi-disciplinary teams drawn from our network to deliver environmental sustainability improvements across the value chain.

Technology Strategy

Technology Strategy acts as one voice of the industry to define strategy, accelerate technology transformation and support technology translation and adoption. With a purpose of enabling the future state of flexible, resilient, sustainable end-to-end biomanufacturing.

DOWNLOAD
An industry perspective on understanding AAV capsid content variants
Needle On Yellow Background
EXTERNAL-RESOURCE
An intercompany perspective on practical experiences of predicting, optimizing and analyzing high concentration biologic therapeutic formulations
DOWNLOAD
The Drug Substance 2.0 Strategic Value Framework
Coloured dots on teal, next to vial
DOWNLOAD
BioPhorum’s holistic approach to container closure integrity
Magnifying glass over a tablet all coloured blue
DOWNLOAD
Digital Plant Maturity Model 3.0
NEWS
Inaugural BioPhorum Quality face to face – get involved
PODCAST
The next step in building regulatory as a capability to enable strategic innovation across the BioPhorum community
NEWS
A launchpad for an improved CGT outbound supply chain
DNA and Earth on blue background
DOWNLOAD
A vision for the biopharmaceutical industry’s inbound supply chain
NEWS
Building a resilient business means adopting water stewardship
Technology Roadmap V 2.0
DOWNLOAD
BioPhorum Technology Roadmapping roadmap vision 2.0

Publications

Documents including best practices, vision statements and peer reviewed papers to help you take value back to your business.

Webinars

Discussing all aspects of the biopharmaceutical industry, from digitization and knowledge management to raw materials, supply chain, sustainability and more. Learn from the perspectives of those at the forefront of the industry.

Podcasts

BioPhorum Connect is our podcast series that keeps you up to date with the latest news and trends in the biopharmaceutical industry. From experienced professionals to thought leaders, these podcasts bring you the insights and perspectives of experts from around the world.

Tools

A variety of resources including design tools and user requirement specifications to help you improve and streamline your business processes.

Benchmarks and Surveys

Research conducted among the BioPhorum membership providing evidence to support change and identify best practice.

Browse all

Access a variety of free tools and papers and other resources designed to provide you with up-to-date information and insights to help you make informed decisions and maximize your success. Access our resources today and start making improving and streamlining your business processes.

WEBINAR
Bioreactivity testing in single-use system biomanufacturing
WEBINAR
Bioreactivity testing in single-use system biomanufacturing
WEBINAR
Bioreactivity testing in single-use system biomanufacturing
Magnifying glass over a tablet all coloured blue
DOWNLOAD
Digital Plant Maturity Model 3.0
WEBINAR
Bioreactivity testing in single-use system biomanufacturing